<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4406</id>
  <title>T3D4352</title>
  <common-name>Glutathione</common-name>
  <description>Glutathione is a compound synthesized from cysteine, perhaps the most important member of the body's toxic waste disposal team. Like cysteine, glutathione contains the crucial thiol (-SH) group that makes it an effective antioxidant. There are virtually no living organisms on this planet-animal or plant whose cells don't contain some glutathione. Scientists have speculated that glutathione was essential to the very development of life on earth. Glutathione has many roles; in none does it act alone. It is a coenzyme in various enzymatic reactions. The most important of these are redox reactions, in which the thiol grouping on the cysteine portion of cell membranes protects against peroxidation; and conjugation reactions, in which glutathione (especially in the liver) binds with toxic chemicals in order to detoxify them. Glutathione is also important in red and white blood cell formation and throughout the immune system. glutathione's clinical uses include the prevention of oxygen toxicity in hyperbaric oxygen therapy, treatment of lead and other heavy metal poisoning, lowering of the toxicity of chemotherapy and radiation in cancer treatments, and reversal of cataracts. Glutathione participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It is also important as a hydrophilic molecule that is added to lipophilic toxins and waste in the liver during biotransformation before they can become part of the bile. Glutathione is also needed for the detoxification of methylglyoxal, a toxin produced as a by-product of metabolism. This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I (EC 4.4.1.5) catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-Lactoyl-glutathione. Glyoxalase II (EC 3.1.2.6) catalyzes the hydrolysis of S-D-Lactoyl-glutathione to glutathione and D-lactate. GSH is known as a substrate in both conjugation reactions and reduction reactions, catalyzed by glutathione S-transferase enzymes in cytosol, microsomes, and mitochondria. However, it is also capable of participating in non-enzymatic conjugation with some chemicals, as in the case of n-acetyl-p-benzoquinone imine (NAPQI), the reactive cytochrome P450-reactive metabolite formed by acetaminophen, that becomes toxic when GSH is depleted by an overdose (of acetaminophen). Glutathione in this capacity binds to NAPQI as a suicide substrate and in the process detoxifies it, taking the place of cellular protein thiol groups which would otherwise be covalently modified; when all GSH has been spent, NAPQI begins to react with the cellular proteins, killing the cells in the process. The preferred treatment for an overdose of this painkiller is the administration (usually in atomized form) of N-acetylcysteine, which is used by cells to replace spent GSSG and renew the usable GSH pool.  It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.</description>
  <cas>70-18-8</cas>
  <pubchem-id>124886</pubchem-id>
  <chemical-formula>C10H17N3O6S</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>195°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>292.5 mg/mL</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Glutathione (GSH) participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It is also important as a hydrophilic molecule that is added to lipophilic toxins and waste in the liver during biotransformation before they can become part of the bile. Glutathione is also needed for the detoxification of methylglyoxal, a toxin produced as a by-product of metabolism. This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-Lactoyl-glutathione. Glyoxalase II catalyzes the conversion of S-D-Lactoyl Glutathione to Reduced Glutathione and D-lactate. GSH is known as a cofactor in both conjugation reactions and reduction reactions, catalyzed by glutathione S-transferase enzymes in cytosol, microsomes, and mitochondria. However, it is capable of participating in non-enzymatic conjugation with some chemicals, as it is hypothesized to do to a significant extent with n-acetyl-p-benzoquinone imine (NAPQI), the reactive cytochrome P450 reactive metabolite formed by toxic overdose of acetaminophen. Glutathione in this capacity binds to NAPQI as a suicide substrate and in the process detoxifies it, taking the place of cellular protein sulfhydryl groups which would otherwise be toxically adducted. The preferred medical treatment to an overdose of this nature, whose efficacy has been consistently supported in literature, is the administration (usually in atomized form) of N-acetylcysteine, which is used by cells to replace spent GSSG and allow a usable GSH pool.</mechanism-of-toxicity>
  <metabolism></metabolism>
  <toxicity>ORL-MUS LD&lt;sub&gt;50&lt;/sub&gt; 5000 mg/kg, IPR-MUS LD&lt;sub&gt;50&lt;/sub&gt; 4020 mg/kg, SCU-MUS LD&lt;sub&gt;50&lt;/sub&gt; 5000 mg/kg, IVN-RBT LD&lt;sub&gt;50&lt;/sub&gt; &gt; 2000 mg/kg, IMS-MUS LD&lt;sub&gt;50&lt;/sub&gt; 4000 mg/kg</toxicity>
  <lethaldose></lethaldose>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For nutritional supplementation, also for treating dietary shortage or imbalance</use-source>
  <min-risk-level></min-risk-level>
  <health-effects></health-effects>
  <symptoms></symptoms>
  <treatment></treatment>
  <created-at type="dateTime">2014-08-29T06:32:13Z</created-at>
  <updated-at type="dateTime">2026-05-14T16:24:15Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Glutathione</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C00051</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>16856</chebi-id>
  <biocyc-id>OXIDIZED-GLUTATHIONE</biocyc-id>
  <ctd-id></ctd-id>
  <stitch-id></stitch-id>
  <drugbank-id>DB00143</drugbank-id>
  <pdb-id>GSH</pdb-id>
  <actor-id></actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O</moldb-smiles>
  <moldb-formula>C10H17N3O6S</moldb-formula>
  <moldb-inchi>InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1</moldb-inchi>
  <moldb-inchikey>RWSXRVCMGQZWBV-WDSKDSINSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">307.323</moldb-average-mass>
  <moldb-mono-mass type="decimal">307.083805981</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-6.4</logp>
  <hmdb-id>HMDB00125</hmdb-id>
  <chembl-id>CHEMBL1543</chembl-id>
  <chemspider-id>111188</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Akihiro Mizutani, &amp;#8220;Complexes of polysaccharides or derivatives thereof with reduced glutathione and process for preparing said complexes.&amp;#8221; U.S. Patent US4009264, issued February, 1971.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003312</chemdb-id>
  <dsstox-id>DTXSID6023101</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00001243</susdat-id>
  <iupac>(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid</iupac>
  <moldb-polar-surface-area>158.82000000000002</moldb-polar-surface-area>
  <moldb-refractivity>69.11490000000002</moldb-refractivity>
  <moldb-polarizability>29.11283212542198</moldb-polarizability>
  <moldb-rotatable-bond-count>9</moldb-rotatable-bond-count>
  <moldb-acceptor-count>7</moldb-acceptor-count>
  <moldb-donor-count>6</moldb-donor-count>
  <moldb-pka-strongest-acidic>1.9364037247697885</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>9.223740958320658</moldb-pka-strongest-basic>
  <moldb-physiological-charge>-1</moldb-physiological-charge>
  <moldb-number-of-rings>0</moldb-number-of-rings>
  <moldb-alogps-logp>-2.74</moldb-alogps-logp>
  <moldb-alogps-logs>-2.54</moldb-alogps-logs>
  <moldb-alogps-solubility>8.79e-01 g/l</moldb-alogps-solubility>
</compound>
